On February 17, 2026, this newsletter featured 5 insider purchases detected from SEC Form 4 filings.
📈 Daily Insider & Cluster Buy Highlights – February 17, 2026
Here are some of the most interesting insider and cluster buying signals from the last 7 days.
⚠️ For information purposes only.
This information is provided for informational purposes only and does not constitute investment advice, financial advice, trading advice, or any other type of advice. All investments carry risk, including the potential loss of principal. Past performance is not indicative of future results. You should consult with a qualified financial advisor, accountant, or other professional before making any investment decisions. The information contained in this newsletter is not intended to be a substitute for professional financial advice.
📊 About Fair Value:
The Fair Value shown for each company is calculated using a Levered Discounted Cash Flow (DCF) model. This method estimates the intrinsic value of a stock by projecting future cash flows and discounting them back to present value, accounting for the company's debt structure. A positive percentage difference indicates the stock may be undervalued relative to this model, while a negative percentage suggests it may be overvalued. Fair value calculations are estimates and should be considered alongside other factors.
🔥 Notable Cluster Buys (≥ $500,000)
No new qualifying cluster buys in the last 7 days.
💼 Notable Individual Insider Buys (≥ $100,000)
Director
Second Sight Medical Products, Inc. ($EYES)
Transaction Date: Feb 15, 2026
Shares: 1,601,941
Purchase Price: $1.03
Purchase Value: $1,649,999
📈
P&L: 301.9% ($4,982,037 gain)
Director
Second Sight Medical Products, Inc. ($EYES)
Transaction Date: Feb 15, 2026
Shares: 264,551
Purchase Price: $1.26
Purchase Value: $333,334
📈
P&L: 228.6% ($761,907 gain)
N/A
Personalis, Inc. ($PSNL)
Transaction Date: Dec 19, 2025
Shares: 29,641
Purchase Price: $8.39
Purchase Value: $248,688
📉
P&L: 2.1% ($5,335 loss)
📊 Valuation & Analyst Info:
Analyst Rating: C
Avg Price Target: $12.00 (+46.2% vs current)
📰 Recent News (Last 7 Days):
Benzinga • Feb 10, 2026
Personalis (PSNL) stock up in premarket on Medicare coverage for its NeXT Personal test for lung cancer surveillance.
Business Wire • Feb 10, 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage for the company's NeXT Personal molecular res...
📅 Upcoming Earnings: Feb 26, 2026
EPS Estimate: $-0.31
N/A
Personalis, Inc. ($PSNL)
Transaction Date: Dec 18, 2025
Shares: 31,430
Purchase Price: $7.91
Purchase Value: $248,611
📈
P&L: 3.8% ($9,429 gain)
📊 Valuation & Analyst Info:
Analyst Rating: C
Avg Price Target: $12.00 (+46.2% vs current)
📰 Recent News (Last 7 Days):
Benzinga • Feb 10, 2026
Personalis (PSNL) stock up in premarket on Medicare coverage for its NeXT Personal test for lung cancer surveillance.
Business Wire • Feb 10, 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage for the company's NeXT Personal molecular res...
📅 Upcoming Earnings: Feb 26, 2026
EPS Estimate: $-0.31
Director
Northpointe Bancshares, Inc. ($NPB)
Transaction Date: Feb 11, 2026
Shares: 14,205
Purchase Price: $16.90
Purchase Value: $240,064
📈
P&L: 4.1% ($9,801 gain)
📊 Valuation & Analyst Info:
Analyst Rating: B+
Avg Price Target: $20.00 (+13.7% vs current)
This newsletter is generated automatically. Please verify all information independently before making investment decisions.
